Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, '18 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
Thermo Fisher (TMO) Beats on Q1 Earnings & Sales Estimates
by Zacks Equity Research
Thermo Fisher (TMO) has launched innovative new products in the key technology platforms.
Medical Product Stock Earnings Roster for Apr 25: LH & More
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
What's in the Offing for Thermo Fisher (TMO) in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) benefits from its acquisition of FEI, consistently adding stimulus to its analytical instruments portfolio for over a year now.
Thermo Fisher Strong on Global Business Amid Forex Woes
by Zacks Equity Research
Thermo Fisher (TMO) witnesses solid growth globally. Foreign exchange headwinds remain.
LabCorp Forms Lab-Alliance With Kentucky-Based Health Firm
by Zacks Equity Research
The multi-year, comprehensive laboratory deal to help LabCorp (LH) provide high-quality, high-value and standardized laboratory diagnostics for Appalachian Regional Healthcare.
The Zacks Analyst Blog Highlights: Amgen, FedEx, Thermo Fisher, Sherwin-Williams and Ameriprise
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, FedEx, Thermo Fisher, Sherwin-Williams and Ameriprise
Top Stock Reports for Amgen, FedEx & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), FedEx (FDX) and Thermo Fisher (TMO).
Thermo Fisher Scientific Buys IntegenX, Widens HID Suite
by Zacks Equity Research
Thermo Fisher Scientific (TMO) forges ahead with initiatives to strengthen its hold in the high-potential human identification market.
Thermo Fisher Grows on New Buyouts Amid Tough Competition
by Zacks Equity Research
Thermo Fisher's (TMO) acquisition of FEI Company already adds capabilities to its analytical instruments portfolio. Also, solid cash in hand enables the company to yield fat returns to investors.
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Lines
by Zacks Equity Research
Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.
Thermo Fisher (TMO) Beats on Q4 Earnings & Sales Estimates
by Zacks Equity Research
Thermo Fisher (TMO) rides high on strength in all segments in Q4.
Why Earnings Season Could Be Great for Thermo Fisher (TMO)
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Thermo Fisher's (TMO) Product Portfolio Up Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) already derives synergies from the acquisition of FEI that largely adds capabilities to its analytical instruments portfolio.
Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq
by Zacks Equity Research
Illumina (ILMN) consistently tries to enhance NGS platform.
Are Interest Rates Really Going Up?
by Sheraz Mian
The odds of interest rates going up meaningfully are not as far-fetched as many likely in the market believe.
Pacific Biosciences Hurt by Competition in Niche Markets
by Zacks Equity Research
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
Top Research Reports for Microsoft, Intel & UnitedHealth
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Intel (INTC) and UnitedHealth (UNH).
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments
by Zacks Equity Research
On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.
Can AngioDynamics (ANGO) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
AngioDynamics (ANGO) to gain from solid product portfolio and demand for Solero MTA system. However, unfavorable estimates are a concern.
Global In Vitro Diagnostic Market Booms: Stocks in Focus
by Zacks Equity Research
With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.
IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.
Luminex (LMNX) Tops Q3 Earnings, Meets Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) third quarter saw a strong top line, solid cash flow as well as profits in Q3. The company's Assay business is likely to drive growth over the long term.
Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up
by Zacks Equity Research
On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.
Thermo Fisher (TMO) Beats on Q3 Earnings & Sales Estimates
by Zacks Equity Research
Thermo Fisher (TMO) rides high in Q3 banking on its analytical instruments segment in particular.